Ana Konvalinka, PhD, MD, FRCPC

Dr. Ana Konvalinka was recruited in 2015, as a transplant nephrologist and a Clinician Scientist at Toronto General Hospital, University Health Network. She is an Assistant Professor at the University of Toronto. Dr. Konvalinka completed medical studies at the University of Ottawa in 2003. She then completed internal medicine and nephrology training in Toronto in 2008. She subsequently embarked on a PhD in basic science at the University of Toronto. Her PhD thesis addressed the effect of angiotensin II on the proteome of primary human proximal tubular cells, and the relevance of this effect in vivo. Following completion of her PhD in 2013, she went on to complete the clinical kidney transplant fellowship at Toronto General Hospital. Her main clinical and research interests are in antibody-mediated rejection and kidney allograft fibrosis. She utilizes systems biology approaches and proteomics to enhance the understanding of the mechanisms, derive novel markers and to repurpose drugs for treatment of kidney disease. Dr. Konvalinka is the director of the Multi-Organ Transplant biobank for kidney, pancreas and liver transplant programs. She is also the co-director of the Drug Discovery research group. She has received international research awards (the Human Proteome Project (2016), the American Society of Transplantation Faculty-Development Research Grant (2016) and the Advances in Organ Transplantation Award (2015)) and national research awards (Canadian Society of Nephrology New Investigator Lectureship (2017) and the KRESCENT New Investigator Award (2016)).

Dr. Konvalinka’s research program is focused on the following three areas:

1. Native and allograft kidney fibrosis represents the final common process of organ failure. Unfortunately, there are currently no effective treatments for kidney fibrosis. The development of novel therapies has been hampered, at least in part, by the lack of early, non-invasive markers of fibrosis. We have identified a group of proteins regulated by a prototypical fibrogenic stimulus, angiotensin II, in kidney cells in vitro and demonstrated that these proteins were involved in kidney fibrosis in vivo. Using mass spectrometry-based assays, we have demonstrated that urine measurements of these proteins reflect kidney allograft fibrosis. We are now examining the ability of our urine fibrosis signature proteins to identify fibrosis early in kidney transplant recipients. We are also studying the mechanisms of regulation of these fibrosis signature proteins. Agents that inhibit these proteins may represent new potential treatments of kidney disease.

2. Antibody-mediated rejection is the leading cause of premature kidney allograft loss. Pathophysiology of antibody-mediated rejection is incompletely understood and therapeutic options are limited. This type of rejection is linked to antibodies directed against the donor allograft, however, not all antibodies lead to allograft injury. What remains unclear is how early kidney antibody-mediated injury in AMR is initiated and perpetuated by the antibodies. We are utilizing systems biology and proteomics approaches to identify compartment-specific proteome changes in antibody-mediated injury and antibodies more likely to cause graft injury. We will also be utilizing single cell analyses of kidney allograft biopsies to understand the interactions between immune and parenchymal cells in the kidney microenvironment. We aim to identify new therapeutic targets of antibody-mediated rejection.

3. Male sex has been associated with increased risk of progression of kidney disease, but the mechanisms underpinning this phenomenon are poorly understood. We have recently discovered that male sex hormones affect metabolic enzymes in kidney cells and may result in maladaptive changes in the kidney. Interestingly, male kidney cells demonstrate alterations in metabolism, compared to female kidney cells and these alterations are further accentuated by male sex hormones. We are now investigating how sex hormones and sex of the cell affect metabolism and whether we can modify the maladaptive changes in male cells through manipulation of metabolism.

Transplantation. 2019 Feb 19;:
Mohammed Ali Z, Tokar T, Batruch I, Reid S, Tavares-Brum A, Yip P, Cardinal H, Hébert MJ, Li Y, Kim SJ, Jurisica I, John R, Konvalinka A
Med Mycol Case Rep. 2018 Sep;21:20-22
Guenette A, Husain S, Konvalinka A, Geddie W, Rotstein C
Lab Invest. 2018 Jun 08;:
Clotet-Freixas S, Soler MJ, Palau V, Anguiano L, Gimeno J, Konvalinka A, Pascual J, Riera M
Transplantation. 2018 Apr 21;:
Hamar M, Urbanellis P, Kaths MJ, Kollmann D, Linares I, Ganesh S, Wiebe A, Cen JY, Yip PM, John R, Konvalinka A, Mucsi I, Ghanekar A, Bagli D, Grant DR, Robinson LA, Selzner M
Can J Kidney Health Dis. 2017;4:2054358117740583
Molnar AO, Barua M, Konvalinka A, Schick-Makaroff K
Kidney Int. 2017 Jun;91(6):1347-1361
Bae EH, Fang F, Williams VR, Konvalinka A, Zhou X, Patel VB, Song X, John R, Oudit GY, Pei Y, Scholey JW
J Am Soc Nephrol. 2017 Apr;28(4):1050-1061
Van JA, Scholey JW, Konvalinka A
Mol Cell Proteomics. 2017 Mar;16(3):368-385
Clotet S, Soler MJ, Riera M, Pascual J, Fang F, Zhou J, Batruch I, Vasiliou SK, Dimitromanolakis A, Barrios C, Diamandis EP, Scholey JW, Konvalinka A
Clin Proteomics. 2016;13:16
Konvalinka A, Batruch I, Tokar T, Dimitromanolakis A, Reid S, Song X, Pei Y, Drabovich AP, Diamandis EP, Jurisica I, Scholey JW
Diabetologia. 2015 Jul;58(7):1668-78
Fang F, Bae EH, Hu A, Liu GC, Zhou X, Williams V, Maksimowski N, Lu C, Konvalinka A, John R, Scholey JW

Pages


Transplant Nephrologist, Department of Medicine, Division of Nephrology, University Health Network
Assistant Professor, Department of Medicine and Institute of Medical Science, University of Toronto